| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/09/2011 | EP2292273A2 Remodeling and glycoconjugation of peptides |
| 03/09/2011 | EP2292271A2 Remodelling and glycoconjugation of an antibody |
| 03/09/2011 | EP2292268A1 Pharmaceutical composition for use in treatment of diabetes |
| 03/09/2011 | EP2292251A1 Combination therapy using anti-angiogenic agents and TNF-alpha |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292232A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II |
| 03/09/2011 | EP2292225A1 Dosage form comprising taxol in crystalline form |
| 03/09/2011 | EP2291372A2 Intestinal alkaline phosphatase modulators and uses thereof |
| 03/09/2011 | EP2291183A2 Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 03/09/2011 | EP2079747B1 Heterocyclic compounds useful as anabolic agents for livestock animals |
| 03/09/2011 | EP1748069B1 Follistatin mutant polypeptide |
| 03/09/2011 | EP1513812B1 Substituted indoles |
| 03/09/2011 | EP1499297B1 Pharmaceutical formulation comprising atorvastatin calcium |
| 03/09/2011 | EP1497279B1 Substituted indoles and their use as 5ht-reuptake inhibitors and as 5ht ligands |
| 03/09/2011 | EP1355910B1 Formulation of boronic acid compounds |
| 03/09/2011 | EP1315513B1 "pseudo"-native chemical ligation |
| 03/09/2011 | EP1276887B1 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors |
| 03/09/2011 | EP1088098B1 Medicament for treating hiv-infected mammals |
| 03/09/2011 | CN101983627A Application of epigallocatechin gallate (EGCG) in intervention of fetal alcohol-related diseases |
| 03/09/2011 | CN101068560B Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and Vero toxin-neutralizing agent |
| 03/08/2011 | US7902399 Fatty acids analogous |
| 03/08/2011 | US7902255 γ-butyrolactone compound and pharmaceutical composition thereof |
| 03/08/2011 | US7902179 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease |
| 03/08/2011 | US7902170 Influenza virus binding, sialylated oligosaccharide substance and use thereof |
| 03/08/2011 | US7902164 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/08/2011 | US7902144 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 03/08/2011 | US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 03/08/2011 | US7901894 Kinase inhibitors |
| 03/08/2011 | US7901879 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 03/08/2011 | US7901874 Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901706 Liposomes, micelles, polyelectrolytes; contact lenses; films; drug delivery; gene therapy |
| 03/08/2011 | US7901683 Methods of inhibiting amyloid toxicity |
| 03/08/2011 | US7901678 Medicinal compositions containing Fc receptor γ chain activator |
| 03/08/2011 | CA2487532C Pyrrolidine derivatives as oxytocin antagonists |
| 03/08/2011 | CA2486915C Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | CA2468691C 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists |
| 03/08/2011 | CA2464721C Nitrogenous (tetrahydropyridyl) (alkyl) heterocycles with tnf activity |
| 03/08/2011 | CA2434272C Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 03/08/2011 | CA2420899C Hydroxamate derivatives useful as deacetylase inhibitors |
| 03/08/2011 | CA2415396C 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 03/08/2011 | CA2413334C Stabilized interleukin 2 |
| 03/08/2011 | CA2361251C Formulations comprising antisense nucleotides to connexins |
| 03/08/2011 | CA2343840C Use of a cytokine-producing lactococcus strain to treat colitis |
| 03/08/2011 | CA2311734C Flash-melt oral dosage formulation |
| 03/08/2011 | CA2137377C Retinal pigmented epithelium derived neurotrophic factor |
| 03/03/2011 | WO2011025368A1 Method of treating frailty |
| 03/03/2011 | WO2011025050A1 Apoptosis inducer |
| 03/03/2011 | WO2011025006A1 Gpr119 agonist |
| 03/03/2011 | WO2011024987A1 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same |
| 03/03/2011 | WO2011024955A1 Nucleic acid capable of binding to tgf-βii-type receptor, and use thereof |
| 03/03/2011 | WO2011024942A1 Matrix metalloprotease-2 (mmp-2) inhibitor |
| 03/03/2011 | WO2011024932A1 Novel tetrahydroisoquinoline compounds |
| 03/03/2011 | WO2011024874A1 Base addition salts |
| 03/03/2011 | WO2011024873A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | WO2011024872A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | WO2011024871A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | WO2011024869A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | WO2011024822A1 Diagnosis marker, diagnosis method and therapeutic agent for amyotrophic lateral sclerosis, and animal model and cell model developing amyotrophic lateral sclerosis |
| 03/03/2011 | WO2011024763A1 Prophylaxis, therapeutic agent, or anorexiant for diabetes |
| 03/03/2011 | WO2011024711A1 Novel compound amycolose derivative, and production process and use of same |
| 03/03/2011 | WO2011024550A1 Method for efficient production of induced pluripotent stem cells utilizing cells derived from oral mucosa |
| 03/03/2011 | WO2011024480A1 Drug composition for angiogenesis therapy |
| 03/03/2011 | WO2011024468A1 Novel sulfonamide derivative and pharmaceutical product containing same |
| 03/03/2011 | WO2011022786A1 Methods for diagnosis and treatment of chronic fatigue syndrome |
| 03/03/2011 | US20110054237 Methods and Systems for Magnetic Focusing of Therapeutic, Diagnostic or Prophylactic Agents to Deep Targets |
| 03/03/2011 | US20110054159 Rna interference mediating small rna molecules |
| 03/03/2011 | US20110054010 Transcription Factor Decoys And Use Thereof |
| 03/03/2011 | US20110054003 Antisense oligonucleotide modulation of stat3 expression |
| 03/03/2011 | US20110053954 Method of treatment and/or prevention of brain, spinal or nerve injury |
| 03/03/2011 | US20110053903 Pharmaceutical compositions based on azetidine derivatives |
| 03/03/2011 | US20110053881 6-Disubstituted Or Unsaturated Bicyclic Nucleic Acid Analogs |
| 03/03/2011 | US20110053865 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| 03/03/2011 | US20110053844 Liquid formulation of g-csf conjugate |
| 03/03/2011 | US20110053830 Methods for treating septic shock |
| 03/03/2011 | US20110053217 Polynucleotides encoding signal peptide-containing molecules |
| 03/03/2011 | US20110052733 Herbal compositions for the treatment of mucosal lesions |
| 03/03/2011 | US20110052721 Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses |
| 03/03/2011 | US20110052702 Method and Apparatus for Producing Organic Nanotubes |
| 03/03/2011 | US20110052676 Composition For Delaying Cellular Senescence |
| 03/03/2011 | US20110052673 Therapeutic compositions |
| 03/03/2011 | US20110052670 Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 03/03/2011 | US20110052659 Implants for administering substances and methods of producing implants |
| 03/03/2011 | US20110052643 Compounds for inflammation and immune-related uses |
| 03/03/2011 | US20110052604 Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors |
| 03/03/2011 | US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses |
| 03/03/2011 | US20110052545 Regeneration system, its production and use |
| 03/03/2011 | US20110052537 Nitro-based explosive remediation |
| 03/03/2011 | US20110052529 Methods and compositions for expanding t regulatory cells |
| 03/03/2011 | US20110052504 Contrast agents |
| 03/03/2011 | CA2790390A1 Novel tetrahydroisoquinoline compounds |
| 03/03/2011 | CA2771833A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | CA2759815A1 Method of treating frailty |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289894A2 Pyrrolo-triazine compounds useful as kinase inhibitors |
| 03/02/2011 | EP2289876A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 03/02/2011 | EP2289848A2 Therapeutic malonic acid/acetic acid C60 tri-adducts of Buckminsterfullerene and methods related to thereto |
| 03/02/2011 | EP2289556A2 Pharmaceutical composition for use in treatment of diabetes |
| 03/02/2011 | EP2289555A1 Method of treating frailty |
| 03/02/2011 | EP2289540A1 Alpha-1-antitrypsin for use in the treatment of chronic fatigue syndrome |